Our top pick for
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Ligand Pharmaceuticals Incorporated is a biotechnology business based in the US. Ligand Pharmaceuticals Incorporated shares (LGND) are listed on the NASDAQ and all prices are listed in US Dollars. Ligand Pharmaceuticals Incorporated employs 155 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$150.21|
|52-week range||$78.26 - $219.75|
|50-day moving average||$152.68|
|200-day moving average||$125.99|
|Wall St. target price||$221.14|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$28.29|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-05-07)||N/A|
|1 month (2021-04-16)||-0.01%|
|3 months (2021-02-18)||3.67%|
|6 months (2020-11-18)||84.35%|
|1 year (2020-05-18)||44.63%|
|2 years (2019-05-17)||30.98%|
|3 years (2018-05-18)||194.99|
|5 years (2016-05-18)||24.83%|
Valuing Ligand Pharmaceuticals Incorporated stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Ligand Pharmaceuticals Incorporated's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Ligand Pharmaceuticals Incorporated's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.6975. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Ligand Pharmaceuticals Incorporated's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Ligand Pharmaceuticals Incorporated's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $57.4 million.
The EBITDA is a measure of a Ligand Pharmaceuticals Incorporated's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$186.4 million|
|Operating margin TTM||15.79%|
|Gross profit TTM||$96.6 million|
|Return on assets TTM||1.29%|
|Return on equity TTM||-0.4%|
|Market capitalisation||$2.4 billion|
TTM: trailing 12 months
There are currently 1.6 million Ligand Pharmaceuticals Incorporated shares held short by investors – that's known as Ligand Pharmaceuticals Incorporated's "short interest". This figure is 4.5% up from 1.5 million last month.
There are a few different ways that this level of interest in shorting Ligand Pharmaceuticals Incorporated shares can be evaluated.
Ligand Pharmaceuticals Incorporated's "short interest ratio" (SIR) is the quantity of Ligand Pharmaceuticals Incorporated shares currently shorted divided by the average quantity of Ligand Pharmaceuticals Incorporated shares traded daily (recently around 182711.05937136). Ligand Pharmaceuticals Incorporated's SIR currently stands at 8.59. In other words for every 100,000 Ligand Pharmaceuticals Incorporated shares traded daily on the market, roughly 8590 shares are currently held short.
However Ligand Pharmaceuticals Incorporated's short interest can also be evaluated against the total number of Ligand Pharmaceuticals Incorporated shares, or, against the total number of tradable Ligand Pharmaceuticals Incorporated shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Ligand Pharmaceuticals Incorporated's short interest could be expressed as 0.09% of the outstanding shares (for every 100,000 Ligand Pharmaceuticals Incorporated shares in existence, roughly 90 shares are currently held short) or 0.1325% of the tradable shares (for every 100,000 tradable Ligand Pharmaceuticals Incorporated shares, roughly 133 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Ligand Pharmaceuticals Incorporated.
Find out more about how you can short Ligand Pharmaceuticals Incorporated stock.
We're not expecting Ligand Pharmaceuticals Incorporated to pay a dividend over the next 12 months.
Ligand Pharmaceuticals Incorporated's shares were split on a 1:6 basis on 18 November 2010. So if you had owned 6 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Ligand Pharmaceuticals Incorporated shares – just the quantity. However, indirectly, the new 500% higher share price could have impacted the market appetite for Ligand Pharmaceuticals Incorporated shares which in turn could have impacted Ligand Pharmaceuticals Incorporated's share price.
Over the last 12 months, Ligand Pharmaceuticals Incorporated's shares have ranged in value from as little as $78.26 up to $219.75. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Ligand Pharmaceuticals Incorporated's is 1.1969. This would suggest that Ligand Pharmaceuticals Incorporated's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. The company's commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19; Teriparatide injection product for the treatment of osteoporosis; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of PPD; Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of postmenopausal osteoporosis; Aziyo portfolio of commercial pericardial repair and CanGaroo envelope extracellular matrix products; Exemptia for autoimmune diseases; Vivitra for breast cancer; Bryxta and Zybev for various indications; and Minnebro for the treatment of hypertension. The company's partners programs, which are in clinical development used for the treatment of cancer, seizure, diabetes, cardiovascular disease, muscle wasting, liver disease, and kidney, and other diseases. In addition, the company is involved in the sale of Captisol materials. Ligand Pharmaceuticals Incorporated was founded in 1987 and is headquartered in San Diego, California. .
Everything we know about the TC Bancshares IPO, plus information on how to buy in.
Everything we know about the Soulgate IPO, plus information on how to buy in.
Everything we know about the Alzamend Neuro IPO, plus information on how to buy in.
Everything we know about the Singular Genomics Systems IPO, plus information on how to buy in.
Everything we know about the Golden Sun Education Group Limited IPO, plus information on how to buy in.
Everything we know about the Phillips Edison & Company IPO, plus information on how to buy in.
Everything we know about the FIGS IPO, plus information on how to buy in.
Everything we know about the DLocal Limited IPO, plus information on how to buy in.
Everything we know about the Torchy’s Tacos IPO, plus information on how to buy in.
Everything we know about the Dutch Bros Coffee IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.